Evidence Generation & Synthesis

Drop your file/s here

Evidence Generation & Synthesis
- Cefiderocol
  - New Level 1 April 11th
  - Folder 1-1-2
Folder 2
- Folder 2-1
  - Folder 2-1-1
  - Folder 2-1-2
Folder 3
- Folder 3-1
  - Folder 3-1-1

Drop your file/s here

Choose file 1

Choose file 2

Choose file 3

Choose publication plan file

Choose support file 1

Choose support file 2

Choose support file 3

FirstName SecondName updated on YYYY/MM/DD HH:MM

Academic Designations:	MSc, Pharmaceutical Medicine, PhD, Ethics and Access to Medicines
Years in Pharmaceutical Industry:	23
Years in Market Access:	13
Expertise in Following Therapeutic Areas:	Oncology, Hematology, Ophthalmology, Central Nervous System, Cardiovascular
Expertise in Following Functions:	Pricing, Evidence Generation & Synthesis
Modeling:	Budget Impact, Cost Effectiveness
Studies:	Real World Evidence (Retrospective, Observational, Matched Cohort, Cost of Burden, Indirect Treatment Comparisons, Systematic Literature Review
Country-specific experience:	US, JA, UK, FR, DE, IT, ES, CH, SE, AU, AT, PT, Middle East and North Africa, CA
Languages Spoken:	English, Hungarian

First Name:

Last Name:

Academic Designations:

Years in Pharmaceutical Industry:

Years in Market Access:

Expertise in Following Therapeutic Areas:

Expertise in Following Functions:

Modeling:

Studies:

Country-specific experience:

Languages Spoken:

Replace Image:

Choose file

Min Vol:

Min Price:

Max Vol:

Max Price:

National:

Regional Min:

Regional Max:

Local Min:

Local Max:

Country:

Regional HTAs:

Region	HTA
Region1

Price:

National Access Determination:

Regional HTAs:

Local Forumlary Status:

List Price Secured vs Forecasted:

Avg Level of Discounts:

Choose file

Select files to move

Toggle All

File 1
File 2
File 3
File 4
File 5
File 6
File 7
File 8

Select destination folder/s

Folder 1
- Folder 1-1
  - Folder 1-1-1
  - Folder 1-1-2
Folder 2

Filename	Uploaded/Edited By	Last Edited
Filename	Firstname Lastname	2022/MM/DD HH:MM:SS
Filename	Firstname Lastname	2021/MM/DD HH:MM:SS
Filename	Firstname Lastname	2020/MM/DD HH:MM:SS

Choose file

Anim pariatur cliche reprehenderit, enim eiusmod high life accusamus terry richardson ad squid. 3 wolf moon officia aute, non cupidatat skateboard dolor brunch. Food truck quinoa nesciunt laborum eiusmod. Brunch 3 wolf moon tempor, sunt aliqua put a bird on it squid single-origin coffee nulla assumenda shoreditch et. Nihil anim keffiyeh helvetica, craft beer labore wes anderson cred nesciunt sapiente ea proident. Ad vegan excepteur butcher vice lomo. Leggings occaecat craft beer farm-to-table, raw denim aesthetic synth nesciunt you probably haven't heard of them accusamus labore sustainable VHS.

Country:

Product:

Packs:

Regulatory timeline

Show

Regulatory Dossier Submission:

Estimate Actual

Regulatory Approval:

Estimate Actual

EU Joint clinical assessment

Show

Pricing and Reimbursement timeline Relevant?

Commercial timeline Relevant?

Distribution model without commercial effort:

Estimate Actual

Commercial Launch Date:

Estimate Actual

Contact Person:

Future price and reimbursement renegotiation Relevant?

Additional Comments:

This document is currently being collaborated on by the following people:

James Percy

Daren Callow

You can open the version of the document saved prior to collaboration via the link below.

This document is currently being collaborated on by the following people:

James Percy

Daren Callow

Date E-mailed	File Name	Folder
02-May-2023	Test Doc for Roy	My Workspace > My Folders > James Folder for Testing	Edit Delete
02-May-2023	Test Doc for Roy		Edit Delete
05-Apr-2023	My File		Edit Delete
20-Mar-2023	xxx		Edit Delete
20-Mar-2023	Testing No Location		Edit Delete
20-Mar-2023	ZIP Test	My Workspace > My Folders > Email Folder 3	Edit Delete
20-Mar-2023	GMA meeting_Hide Ikeoka.png	My Workspace > My Folders > Email Folder 3 > New Folder	Edit Delete

File Upload

File Upload:

Drop your file/s here

File Details

File Title:

Select Locations:

Evidence Generation & Synthesis
- Cefiderocol
  - Development Program
    
    APEKS cUTI
    
    DC Test Aug 23
    
    APEKS NP
    
    CREDIBLE
    
    Large File Test
    
    PK/PD studies
    
    SENTRY
    
    SIDERO CR
    
    SIDERO WT
    
    Y1 2014-2015
    
    Y2 2015-2016
    
    Y3 2016-2017
    
    Y4 2017-2018
  - ITC/NMA
  - Models
    
    BIM EU
    
    archive
    
    BIM US
    
    CEA Model
    
    archive
  - PROs
  - Regulatory
    
    EMA
    
    FDA
  - RWE
  - Scientific Platform
  - SLR
    
    Cefiderocol data
    
    Colistin Adverse Events
    
    outcomes in CR infections
    
    Risk factors for CR infection
    
    Time to effective therapy
  - CARBAR study
  - Other sponsored studies
    
    UK CR costing study
- Ensitrelvir
  - Development Program
    
    Scorpio SR PRO Diaries
  - ITC/NMA
  - Models
  - PROs
    
    COA Dossier
    
    Comprehensibility | Usability
    
    IRB Submission
    
    SCORPIO-HR stimuli
    
    SCORPIO-PEP stimuli
  - Regulatory
    
    Japan EUA
  - RWE
    
    HUB
    
    Extended Team Report Outs
    
    Final Report-outs
    
    Weekly Meetings
    
    WS_1_Long Covid
    
    WS_2_Value Differentiation (Rebound | Resistance)
    
    EHR Project
    
    SLR Project
    
    IncludedPapers
    
    Chan_2021_Suppl
    
    WS_3_Special Populations
    
    Newsletters
  - Scientific Platform
    
    Long covid
  - SLR
    
    aSLR_OH
    
    Final Articles for Inclusion
    
    Final Articles for Inclusion (Updated)
    
    Final Articles for Inclusion (Updated)
    
    Final Articles for Inclusion
    
    TLR
- Lusutrombopag
  - Development Program
    
    CLD TCP
    
    Appendices
    
    Study Sites
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
    
    EMA
    
    Post-authorisation Safety Study
    
    Labels
    
    PMDA
    
    UK_MHRA
    
    PASS
  - RWE
    
    Additional Study Opportunities
    
    Spain
    
    Germany
  - Scientific Platform
    
    References
  - SLR
    
    Burden of PTs
  - Platelet Function Study
  - Presentations to External Experts
- Naldemedine
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- Olorofim
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- Sivopixant
  - Development Program
    
    Competitor Studies
    
    RCC Clinical Studies
    
    RCC Ph 2 (PoC)
    
    RCC Ph 2b
    
    test 3/12
  - ITC/NMA
  - Models
    
    Early Economic Model
    
    Expert Meeting Notes
    
    Final Deliverable (2021)
  - PROs
    
    Concept Elicitation
    
    EoP2b Meeting
    
    Expanded CE_CI Next Phase
    
    FDA Submissions
    
    Meeting_20220712
  - Regulatory
    
    EMA
  - RWE
    
    RWE_ Evidence Generation Sub-team
    
    Experts_CVs
    
    Meetings
    
    M_01152020
    
    M_01302020
    
    M_02122020
    
    M_07132020
    
    M_07272020
    
    M_10042021
    
    M_10082021
    
    M_11022020
    
    Epidemiology
  - Scientific Platform
  - SLR
    
    Comparative Effectiveness
    
    Literature Review
    
    References
  - Cough Characteristics
  - MCDA_Spain
    
    Interviews
    
    Focus Groups
    
    MCDA Results
  - PBO Effect
  - Presentations to External Experts
- BPN14770
  - Development Program
    
    test
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
  - aaaa
    
    bbbb
  - Test inactive
- S-005151
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
  - Adelphi SLR
    
    Adelphi SLR AIS Pubs
  - Presentations to External Experts
  - Targeted Literature Review
    
    Reference Pack
    
    Patients didnt recieve tPA or thrombectomy
    
    Patients where thrombectomy status is unclear
- S-151128
  - Development Program
    
    JP TEST
    
    xxx
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-309309
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-337395
  - Development Program
    
    test
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
    
    EMA
    
    FDA
    
    Type C Meeting RSV Peds COAs
    
    Decision Log
  - RWE
    
    Ped Obs Study
    
    TCRS
    
    WCG Ethics Review Submission Documents
    
    Approval
  - Scientific Platform
  - SLR
  - Adelphi COA Project
    
    CE | CI Study
    
    Study Protoocol
    
    TL Input to inform Draft COAs
    
    Transcripts Caregiver
    
    Transcripts Caregiver (Round 2)
    
    Transcripts Clinician
    
    Transcripts Clinician (Round 2)
    
    De Novo COA Instruments
    
    Ethics
    
    Decision Log
    
    Final Deliverables (COA Landscape Assessment)
    
    Meeting (10.13.22)
    
    Thought Leader Meeting Minutes
  - Adelphi Lit Review: Obs Studies (Peds)
    
    Lit Review Pubs
  - Competitor Protocols in Public Domain
  - GDSC
  - Sharepoint LInks
- S-606001
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-649228
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-740792
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-743229
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
- S-770108
  - Development Program
  - ITC/NMA
  - Models
  - PROs
  - Regulatory
  - RWE
  - Scientific Platform
  - SLR
  - aaaa
  - bbb
    
    ccc
- Medical Plans
Guidelines, Policy & Advocacy
- Guidelines
  - Cefiderocol
    
    Guidelines
  - Ensitrelvir
    
    COVID-19 Long covid Guidelines
  - Lusutrombopag
  - Naldemedine
  - Olorofim
  - Sivopixant
  - BPN14770
  - S-005151
  - S-151128
  - S-309309
  - S-337395
  - S-606001
  - S-649228
  - S-740792
  - S-743229
  - S-770108
- Policy
  - Cefiderocol
    
    AMR
    
    Archive
    
    Bimonthly Newsletter (Global)
    
    Nature Supplement
    
    AMR Toolkit
    
    AMR Toolkit References 2024
    
    references
    
    Cost/Cure Analysis
    
    publications
    
    ISPOR AMR Symposium
    
    xxx 3/12
  - Ensitrelvir
  - Lusutrombopag
  - Naldemedine
  - Olorofim
  - Sivopixant
  - BPN14770
  - S-005151
  - S-151128
  - S-309309
  - S-337395
  - S-606001
  - S-649228
  - S-740792
  - S-743229
  - S-770108
- Advocacy
  - Cefiderocol
  - Ensitrelvir
  - Lusutrombopag
  - Naldemedine
  - Olorofim
  - Sivopixant
  - BPN14770
  - S-005151
  - S-151128
  - S-309309
  - S-337395
  - S-606001
  - S-649228
  - S-740792
  - S-743229
  - S-770108
Dossiers / P&R / HTA
- Cefiderocol
  - Dossiers
    
    AMCP
    
    GVD
    
    archive
    
    WHO EML
  - P&R / HTA
    
    France
    
    CEPS Documents
    
    Dossier submitted
    
    Oral Hearing
    
    Germany
    
    Reserve antibiotic application
    
    Reserve Antibiotic dossier submitted to G-BA
    
    Italy
    
    CPR Dossier update
    
    Inovation Dossier
    
    P&R submission pack AIFA
    
    FETCROJA_Richiesta di prezzo e rimborso
    
    Spain
    
    Fetcroja P&R Submission
    
    TPR allegations and hearing
    
    United Kingdom
    
    UK De-linkage
    
    Cefiderocol
    
    Committee papers
    
    1. Submission
    
    2. stakeholders
    
    3. Experts
    
    4. EEPRU
    
    5. Comments
    
    6. EEPRU response
    
    7. Pre-meeting
    
    Product selection
    
    United States
    
    NTAP 2021 (cUTI)
    
    Presentation to CMS
    
    Submitted Application
    
    Supplemental Information Sent to CMS
    
    ICD-10 PCS
    
    NTAP 2022 (pneumonia)
    
    Belgium
    
    Annex
    
    Canada
    
    preliminay payer research
    
    EUnetHTA
    
    References
    
    Finland
    
    Ireland
    
    Japan
    
    Portugal
    
    AdBoard Nov 2021
    
    Contract
    
    Material
    
    Environmental assessment CTI
    
    Therapeutic report
    
    Sweden
    
    Taiwan
    
    BIA Report
    
    CEA Report
- Ensitrelvir
  - Dossiers
    
    Global Value Dossier
  - P&R / HTA
    
    United Kingdom
  - Rebound
  - Resistance to 3CL-Protease
  - Systematic Literature Reviews
- Lusutrombopag
  - Dossiers
    
    AMCP
    
    GVD
  - P&R / HTA
    
    France
    
    Dossier Development
    
    Germany
    
    Italy
    
    Dossier_Submitted
    
    Negotiation-Related Communication
    
    Spain
    
    Genesis
    
    TPR
    
    United Kingdom
    
    England
    
    avatrombopag
    
    Scotland
- Naldemedine
  - Dossiers
    
    AMCP
    
    GVD
  - P&R / HTA
    
    Belgium
    
    Pricing application - non-reimbursed
    
    Pricing file Rizmoic BE 07MAR2024
    
    08 - Price structure
    
    09 - Justification
    
    France - Transparency Commission
    
    German AMNOG
    
    HILA - Finland
    
    ITALY AIFA
    
    NoMa -Norway
    
    Spain Reimbursement
    
    TLV - Sweden
    
    UK NICE
    
    UK SMC
  - Naldemedine Global Value Dossier
    
    170615_FINAL_Draft_CCD
    
    170615_5thDraft_MarkedUP_CSRs
    
    170615_5thDraft_MarkedUp_RefPack
    
    2019 Naldemedine Global Value Dossier
- Olorofim
  - Dossiers
  - P&R / HTA
- Sivopixant
  - Dossiers
    
    AMCP
    
    GVD
  - P&R / HTA
    
    Germany
    
    Early Advice
    
    Beratungsanforderung (Submission to G-BA)
    
    Ref_Anl1
    
    Ref_Positionspapier
    
    Studienkurzdarstellung
    
    Studienregistereinträge
    
    Response Documents
    
    United Kingdom
- BPN14770
  - Dossiers
  - P&R / HTA
- S-005151
  - Dossiers
  - P&R / HTA
- S-151128
  - Dossiers
  - P&R / HTA
- S-309309
  - Dossiers
  - P&R / HTA
- S-337395
  - Dossiers
  - P&R / HTA
- S-606001
  - Dossiers
  - P&R / HTA
- S-649228
  - Dossiers
  - P&R / HTA
- S-740792
  - Dossiers
  - P&R / HTA
- S-743229
  - Dossiers
  - P&R / HTA
- S-770108
  - Dossiers
  - P&R / HTA
Commercial & Payer Content
- Cefiderocol
  - GCMT Reference Materials
  - Payer Marketing Tools
    
    cost calculator
    
    EU formulary pack
  - Payer-related Research
    
    Canada
    
    Access & Price research - Australia
    
    EU Payer research 2019
    
    Pricing research
    
    materials and report
    
    Questionnaire
    
    Drafts
    
    Report
    
    VMT
    
    Ex-EU5 access research
    
    Olorofim_access pathway assessmet in EU
    
    Syneos Global Access Research
  - 2020_cefiderocol_Global Price guidance
  - Landscape Assessment
- Ensitrelvir
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
    
    Syneos Global Access research
    
    ensitrelvir
- Lusutrombopag
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
    
    European Payer Landscape Research
    
    European PVP and Key Messages
    
    France_MQ_Experts Panel
- Naldemedine
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- Olorofim
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
    
    Access Pathways
- Sivopixant
  - GCMT Reference Materials
    
    GDP
    
    Patient Journey Market Research
    
    Recordings
    
    Japan
    
    United States
    
    Thought Leader Insight
  - Payer Marketing Tools
  - Payer-related Research
    
    DE AMNOG Blueprint
    
    Payer Research (US and Europe)
    
    LCM Project (IC|BPS and rDPN)
- BPN14770
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- S-005151
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
  - Competitor Announcements
  - HCP Research
  - Internal Leadership Presentations
  - Syndicated Reports
  - Texas Ad Board (Feb, 2023)
- S-151128
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- S-309309
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
  - Market Research
- S-337395
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
    
    CRA US_Europe Payer Research
    
    Compliance
    
    FR Blinded Profiles
    
    Meetings_Notes_Slides
    
    KO [July 8 2024]
    
    Reference Materials from GCWG
    
    RSV Payer Survey
    
    MMIT Audio Files
    
    MMIT_Shionogi_RSV IDI_Recordings
    
    MMIT_Shionogi_RSV IDI_Transcripts
    
    RSV Peds Payer Research (Sept 2023)
  - Vaccine Agency Guidance
- S-606001
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- S-649228
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- S-740792
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
    
    CRA US_Europe Payer Research
- S-743229
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
- S-770108
  - GCMT Reference Materials
  - Payer Marketing Tools
  - Payer-related Research
Publications
- Cefiderocol
  - Abstracts
  - Manuscripts
    
    APEKS cUTI
    
    APEKS NP
    
    CREDIBLE
  - Posters
  - Pubs Strategy & Plan
  - Reading References
  - Compassionate Use
- Ensitrelvir
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- Lusutrombopag
  - Abstracts
    
    avatrombopag
    
    Disease State
    
    lusutrombopag
  - Manuscripts
  - Posters
    
    avatrombopag
    
    Disease State
    
    lusutrombopag
  - Pubs Strategy & Plan
  - Reading References
- Naldemedine
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- Olorofim
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- Sivopixant
  - Abstracts
    
    EPI
    
    Measures_Assessment_Tx
    
    Burden
    
    P2X3
    
    gefapixant
    
    Bellus
    
    PROs
  - Manuscripts
  - Posters
    
    Burden
    
    eliapixant
    
    EPI
    
    gefapixant
    
    PRO_Utilities
    
    Bellus
    
    Sivopixant
  - Pubs Strategy & Plan
  - Reading References
    
    Burden
    
    EPI
    
    gefapixant
    
    Guidelines
    
    IC | BPS
    
    Managed Care
    
    Measures_Assessment_Tx
    
    Miscellaneous
    
    Neuromodulators
    
    Pathophysiology
    
    PRO_Utilities
    
    Reviews
  - Presentations (Congresses & Meetings)
- BPN14770
  - Abstracts
    
    Test in Inactive
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-005151
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
    
    Alteplase
    
    Clinical
    
    Economics
    
    mRS
- S-151128
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-309309
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
    
    Patient Reported Endpoints
- S-337395
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-606001
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-649228
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-740792
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-743229
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- S-770108
  - Abstracts
  - Manuscripts
  - Posters
  - Pubs Strategy & Plan
  - Reading References
- Publication Plans
Pricing
- Product Strategy & Policy
  - Cefiderocol
    
    Payer Message Testing
    
    Price Research EU
    
    Pricing Governance
  - Ensitrelvir
    
    New Folder
  - Lusutrombopag
    
    European Pricing Research
    
    Pricing Governance
  - Naldemedine
  - Olorofim
  - Sivopixant
    
    Gefapixant
  - BPN14770
    
    aaaa
    
    aaaaa
    
    bbbb
    
    xxxx
    
    1234
    
    yyyy
    
    zzzz
  - S-005151
  - S-151128
  - S-309309
  - S-337395
  - S-606001
  - S-649228
  - S-740792
  - S-743229
  - S-770108
  - Payer-related Research
gHCVa Capabilities
- MAx Meetings
  - Countries
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    United Kingdom
    
    United States
  - EU MAx
    
    Oct 12-13 Virtual Offsite (2021)
  - GMAx
    
    2023.03_gHCV&AMeeting
    
    2023.07_gHCV&A_Meeting
    
    2024.07_gHCVA & GEE Offsite Washington
    
    Pricing Joint Meeting_GHCVA & Sho-Gai-Bu
    
    00_pricing framework
    
    20230615_kick-off
    
    20230727
    
    20230831
    
    20230921
    
    20231019
    
    20231206
    
    20240123
    
    20240730
  - Products
    
    Cefiderocol
    
    Europe
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    United Kingdom
    
    United States
    
    Ensitrelvir
    
    Lusutrombopaq
    
    Europe
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    2020.05.05
    
    United Kingdom
    
    United States
    
    Naldemedine
    
    Europe
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    United Kingdom
    
    Olorofim
    
    Sivopixant
    
    BPN14770
    
    S-005151
    
    S-151128
    
    S-309309
    
    S-337395
    
    S-606001
    
    S-649228
    
    S-740792
    
    S-743229
    
    S-770108
  - Test Folder
  - Webinars
- MAx Plans
  - Cefiderocol
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    United Kingdom
    
    United States
    
    Global Market Access Plan
  - Ensitrelvir
  - Lusutrombopag
    
    France
    
    Germany
    
    Italy
    
    Spain
    
    United Kingdom
  - Naldemedine
  - Olorofim
  - Sivopixant
  - BPN14770
  - S-005151
  - S-151128
  - S-309309
  - S-337395
  - S-606001
  - S-649228
  - S-740792
  - S-743229
  - S-770108
- Dossiers / HTAs
  - Canada
  - France
  - Germany
  - Global
  - Japan
- Methods
  - Health Utilities
  - MCDA
  - NICE
  - RCTs
- Modeling
  - Cost-effectiveness analysis
  - Early Economic Model_Oncology
  - Relative Pricing Model
- Operating Environment
  - Americas
    
    Canada
    
    LATAM
    
    United States
  - Asia Pacific
  - Europe
  - Middle East and North Africa
- Pricing
  - Asia
    
    Japan
  - Europe
  - Frameworks
    
    Oncology Value Frameworks
    
    ASCO
    
    Guidepoint
  - Germany
  - Pricing Governance
  - Pricing_Projects_Assets
    
    Sakura
    
    Guidepoint_SI
    
    CCR8 for S-531011
    
    HSV
    
    Guidepoint Interviews
    
    mAB_Pain (S-151128)
    
    Pirfenidone (S-770108)
    
    Guidepoint Interviews
    
    PJ Florence_ASD
    
    Pj Florence_HBV
    
    S-637880 MS
    
    S-770108 (SHQ)
    
    EU_Combination and non-inferiority payer interview_202108
    
    US_non-inferiority payer interview and evaluation_202103
- COAs
  - C-PATH
  - COA COE
    
    Blueprint
    
    Glossary
    
    Meeting June 25th
    
    Newsletters
    
    Newsletters _ Archive of old files - do not use
    
    Newsletters _ for REVIEW
    
    Project Management Meetings
    
    Webinars
    
    English
  - COSMIN Tools
  - Europe PRO Study
    
    Stakeholder Facing Content
    
    1. Panellist screener
    
    2. Discussion guide
    
    Team Meeting Notes & Materials
    
    1. Meetings
    
    1. AV/Shionogi kick-off meeting
    
    2. Status updates
    
    1. 20.10.23
    
    10. 11.07.24
    
    11. 22.07.24
    
    12. 25.07.24
    
    13. 29.07.24 (with Prof Guyatt)
    
    2. 16.11.23
    
    3. 19.01.24
    
    4. 31.01.24
    
    5. 19.04.24
    
    6. 26.04.24
    
    7. 01.05.24
    
    8. 17.05.24
    
    9. 20.06.24
    
    3. Advisory Committee kick-off meeting
    
    2. Protocol
    
    3. Timeline
    
    4. HTA Analogue review
    
    1. AC member HTA analogue review outputs
    
    2. Interim summary of HTA analogue insights
  - External Links (Conferences | Webinars)
  - Instruments
    
    Back Pain
    
    PDQ
    
    COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS)
    
    Cough
    
    FACIT_PROMIS
    
    IPF
    
    Stroke
    
    mRS Structured Assessments
  - Landscape Assessments
  - NIHSS Video
  - PRO Round Table (US)
    
    Meeting 1
    
    Meeting 2
    
    Meeting 3
  - Readings
    
    Back Pain
    
    Japan
    
    COPD
    
    Epilepsy
    
    IPF
    
    Obesity
    
    RSV
    
    SF-12
    
    SF-36
    
    Stroke
    
    Barthel Index
    
    mRS
    
    SAQoL-39g
  - Regulatory
  - Training: PRO Modules
    
    Japanese
    
    SHQ MAx Training_Single Lecture
  - Utilities
    
    EQ-5D
    
    NICE
    
    Childhood HRQoL and Utilities
- Value Communication
  - Oncology Value Frameworks
  - References
- Vendor Management
  - A.T. Kearney Limited
    
    SOW_Market Access Capabilities in Rare Disease_09.2023
  - Acaster Lloyd Consulting Ltd
    
    SOW_COA scoping review in Pompe disease_07.2024
  - Accession
    
    SOW_RSV Europe Payer Research_05.2023
    
    SOW_S-531011_Colorectal Cancer EU Payer Insights_02.2024
  - Adelphi
    
    SOW Amendment_: Paediatric RSV - Qualitative Interview: additional interview duration
    
    SOW_C-PATH PRO Consortium Annual Meeting in April 2024_12.2023
    
    SOW_Patient Reported Outcome Project in Europe_08.2023
    
    SOW_RSV_COA Regulatory Support_08.2023
    
    SOW_S-337395_SHI9526H_Exit interviews from the RSV observational study_08.2024
    
    SOW_SHI9526F_Regulatory support in pediatric RSV_03.2024
    
    SOW_SHI9526G_Pediatric RSV observational study - Psychometric validation and UAT_05.2024
    
    SOW_SLR for Acute Ischemic Stroke
    
    SOW_Targeted review pediatric RSV_07.2023
  - AESARA Europe Limited
    
    SOW_EU HTA Awareness Training Materials_01.2024
  - Amaris Consulting UK LTD
  - Analysis Group
    
    SOW_Cefiderocol_US CEA Adaptation_07.2024
    
    SOW_Ensitrelvir_Population Calculator and BIM to Support_2024
    
    SOW_Enstrelvir_CEA and ICER Support_2024
  - Aspen Consulting
  - Astrocyte Consulting
    
    SoW_FXS patient group engagement + 2023 communication
  - BresMed Health Solutions Ltd t/a Lumanity
    
    Bresmed Health Clinical Systematic Literature Review of Colistin Dose...
    
    MSA_BresMed Health Solutions Ltd
    
    SOW_Cefiderocol_Identifying Cefiderocols Contribution to STEDI Values_03.2024
    
    SOW_Zatolmilast_Regulatory Strategy and Review in Fragile X_11.2023
    
    SOW_Zatolmilast_Strategic Regulatory and HTA Planning in EU + UK additional scope_11.2023
    
    SoW_Zatolmilast_Strategic Regulatory and HTA Planning in EU + UK_06.2023
    
    SOW_Zatolmilast_Strategic Support_12.2023
  - C-PATH
  - Catalytic Health
  - Certara
    
    2022 Certara GVD Update
    
    2022 Certara Update PVP Slide deck
    
    2023 Certara GVD revision & Update
    
    Certara consultancy contract
    
    SOW_Cefiderocol OH_08.2023
  - Certara USA Inc
  - Cook
  - COS
  - Courtney Alexander Consulting Ltd
    
    SoW Rizmoic differentiation activities_16.12.2022
    
    SoW Rizmoic messaging for new countries_05.2022
    
    SoW_BPN14770_Global value dossier_05.2022
    
    SoW_BPN14770_GVDValue_03.2023
    
    SoW_Rizmoic editorial support_02.2023
    
    SOW_Rizmoic_Guidelines Pack_06.08.2023
    
    SoW_Rizmoic_Messaging Workshops_07.2023
    
    SoW_Rizmoic_Onbording commercial partners_02.2023
    
    SOW_Rizmoic_Payer OH Slides Realignment_06.08.2023
    
    SoW_Rizmoic_Publication & Reimbursement_03.23
    
    SoW_Rizmoic_Value Training Workshop_03.23
    
    SOW_Zatolmilast_Market Scope_09.2023
  - CRA International (UK) Limited
    
    SOW_Olorofim_Pricing Research_09.2023
    
    SOW_Payer research for BD assessment UK+EU_03.08.2023
    
    SOW_QPEX ANTIINFECTIVES_12.2023
    
    SOW_S-309309_Assessment of payer and patient pricing potential_03.2024
    
    SOW_S-309309_Weight Loss Assessing payer and patient pricing potential - expanded scope_06.2024
    
    SOW_S-337395_RSV Payers_06.2024
    
    SOW_S-740792_P2X7 Indication Payer Value_08.2024
    
    SOW_Zatolmilast_Pricing Strategy EU_08.2023
    
    SOW_Zatolmilast_Pricing Strategy US_06.2023
  - Crystallise Ltd
    
    SOW_Cefiderocol_MBL SRL Burden of Illness_01.2024
    
    SOW_MBL SLR Burden of Illness - Abstracts and Posters_06.2024
    
    SOW_S-217622_SLR for Rebound of Antivirals_10.2023
    
    SOW_S-606001_POMP_20368_Epidemiology_06.2024
    
    SOW_S-606001_POMP_20369_Treatmeant_06.2024
    
    SOW_S-606001_POMP_20370_Burgen_06.2024
    
    SOW_S-606001_POMP_20371_Progression_06.2024
  - Cytel Inc.
    
    Task Order 240190_Cefiderocol_KOL contracting project initiation_02.2024
    
    Task Order 240191_Cefiderocol_DAG dev Data CREDIBLE_03.2024
    
    Task Order 240192_Cefiderocol RWA strategy and protocol synopsis_03.2024
    
    Task Order 240216_Cefiderocol_TDT strategic consulting_03.2024
    
    Task Order 240266_Cefiderocol evidence dissemination RWA_04.2024
    
    Task Order_240092_Cefiderocol CE Stat analysis_04.2024
  - Data Magik Limited
  - Digital Health Labs Limited
  - Ecker+Ecker
    
    DE_AMNOG Blueprint Project (S-600918)
    
    G-BA Early Advice Meeting
  - ELM Medical Limited (UK)
    
    SoW_BPN14770_Account Management 2023
    
    SoW_BPN14770_KOL Engagement 2023
    
    SoW_BPN14770_KOL Mapping + Engagement + Advisory Board_10.01.22
    
    SoW_BPN14770_KOL payments for FXS AB meetings in 2022
    
    SOW_BPN14770_Prep FXS AB November 2023
    
    SoW_BPN14770_Strategy Meeting 1_04.2023
    
    SoW_BPN14770_Strategy Meeting 2 in Q3 2023
    
    SoW_BPN14770_Strategy Meeting 3 in Q4 2023
    
    SOW_Cefiderocol_IEP_08.2023
    
    SOW_EU Launch Options Strategy Meeting_06.2024
    
    SOW_Zatolmilast Market Access Support 2024
    
    SOW_Zatolmilast_IEP Reformatting_11.2023
    
    SOW_Zatolmilast_IEP Update + Scientific Strategy Workshop_02.2024
    
    SOW_Zatolmilast_IEP_08.2023
    
    SOW_Zatolmilast_SUCCEED Phase 1 and stakeholder interviews_06.2024
  - ELM Medical LLC (USA)
    
    SOW_Zatolmilast_US Payer Ad Board logistics_02.24
    
    SOW_Zatolmilast_US Payer Ad Board_12.2023
  - Endpoint Outcomes
  - Epstein Health
  - Estima Scientific Ltd
    
    Finn Kristensen
    
    SOW_Cefiderocol_ITC MAIC Feasibility Assessment_07.2023
  - Europe PRO Initiative (Adelphi Values Ltd)
    
    Andrew Marcellusi (Italy)
    
    Finn Kristensen
    
    Olivier Chassany (France)
    
    Peter Ashley (EP Independent Consultants Limited)
    
    Riber Consultants Ltd / Prof. Mel Calbert
    
    Xavier Badia (CEO Omakase Consulting, Spain)
    
    Yvonne-Beatrice Boehler (Germany)
  - Eversana Life Science Services, LLC
    
    Orders 1 + 2_License agreement renewal_01.2024
    
    SoW_PJ Yellow forecast update_02.2023
  - Evidera
    
    SOW_EVA-39895-00_Cefiderocol_Feasibility assessment_02.2024
  - Facilipharma Ltd
    
    SOW_Rizmoic_Objection Handler Update_07.2024
  - Galbraith
  - Gallagher
  - Genesis Research, LLC
    
    Task Order 18_04.2024
  - GMA Services Ltd
    
    SoW 11_Rizmoic_Naldemedine Reimbursement Belgium_12.2022
    
    SoW 12_BPN14770_FXS landscape assessment Europe
    
    SOW 14_Rizmoic_Reimbursement for Belgium and Netherlands_10.2023
    
    SOW 16_Repurposed medicines + tigecycline_01.2024
    
    SOW 17_FXS Disease Impact Analysis_04.2024
  - HCPs
    
    Domachowske
    
    Munblit
    
    Munoz
    
    PBO Effect
    
    Peter Hawkey / Modus Medica Limited
    
    PRO Europe Advisory Committee
    
    PRO Experts Roundtable
    
    Authorship Agreements
    
    PRO Contract Extensions
    
    PRO Panel_C-PATH
    
    Reeves (Stroke PROs)
    
    Simoes
    
    SLR + CEM (AIS)
    
    Dr. Molina
    
    Dr. Quinn
    
    Stroke SLR Authorship
    
    Swigris
  - HCPs / KOLs for FXS / Zatolmilast
    
    AMC Medical Research B.V (Dr. Agnies van Eeghen)
    
    SA_FXS AB Activities 2023/2024_11.2023
    
    SOW_FXS 1:1 Meeting on 13.01.2023
    
    Clinical Outcomes Solutions LLC (Dr. Tara Symonds)
    
    Dr. Alessandra Murgia
    
    Dr. Rafael de la Torre Fornell
    
    Edinburgh Innovations Limited (Dr. Andrew Stanfield)
    
    Prof. Simon Dixon
    
    SA_FXS AB Activities 2023/2024
    
    Prof. Vincent des Portes
    
    SA_FXA AB Meeting on 02.11.2023
  - Hears Pty Ltd
    
    SOW_Cefiderocol_Reimbursement in Australia_10.2023
  - HEOR (Health Economics &Outcomes Research Ltd)
    
    SOW_BPN14770_FXS CEM Model Development_10.2023
    
    SOW_FXS Advisory Board_12.2022
    
    SOW_FXS clinial trial anylsis methods T&M_04.2024
    
    SOW_Olorofim_Health Economics Model_10.2023
    
    SOW_Olorofim_HTA landscape assessment_06.2024
  - Hogan Lovells
  - ICERA
  - IDEA
  - IHS
  - Illuminate Health Consulting Pty Ltd
  - Insight
  - Insight Medical Research Limited t/a Cello Health Insight
  - IQVIA
    
    SOW_Zatolmilast Regional PMA Capabilities_06.2023 (not signed)
  - JD_Lymon
    
    NTAP_2019
  - Kantar Health
  - KMK Consulting
  - Leadership In Medicine
  - LIM
  - Lumanity Commercial Consulting Inc (under Bresmed Health Solutions Ltd)
    
    MSA_BresMed Health Solutions Ltd
    
    SOW_RSV_KOL Lists_21.08.2023
    
    SOW_Zatolmilast Scientific Strategy Narrative and Workshop Support_02.2024
  - Lumanity Communications Inc (under Bresmed Health Solutions Ltd)
    
    SOW_Zatolmilast Scientific Platform_07.2024
  - MAP Patient Access Limited
  - Mapi Research Trust / Pharmaceutical Research Associates, Inc
    
    Task Order 1_PROs COA Center of Excellence_02.2024
    
    Task Order 2_COA Consultancy Time and Material Service_02.2024
    
    Task Order_S-309309_Targeted Literature Review + COA Landscape Review in Obesity_01.2024
  - Maple Health Group, LLC
  - Market Vision
    
    SOW_S-217622_Covid-19 Patient Journey Research Study_09.2023
    
    SOW_S-309309_Obseity Patient Journey Research Study_01.204
  - Maths in Health B.V
  - McMasters
  - MEK GROUP LLC d/b/a Orangefiery
  - Milliman
  - MMIT
  - Mtech Access Ltd
    
    SOW_Fetcroja BIM_04.2023
  - Mycology Reference Laboratory
  - NDA
  - Nile
  - OHE Consulting Ltd
  - Omakase
    
    MCDA
  - OpenHealth
    
    Amendment_SOW_S-217622_Long Covit SLR-TLR_01.2024
    
    SOW_S-217622_Long Covid Claims Analysis SAP and RWE Consulting_10.2023
    
    SOW_S-217622_Long COVID Regular Updates to Lit Review_02.2024
    
    SOW_S-217622_Long COVID_SLR-TLR_10.2023
    
    SOW_S-217622_Long Covid_Workstreams Strategic Integration_10.2023
  - ORDMs (Other Relevant Decision Makers)
    
    Stephen Sharp
  - Oxford PharmaGenesis Ltd
    
    SOW_Cefiderocol_Meta-Analysis Letter to Editor_01.2024
    
    SOW_Cefiderocol_Meta-Analysis Manuscript_09.2023
    
    SOW_Cefiderocol_Meta-Analysis Technical Report_09.2023
  - Peds RSV Obs Study
    
    TCRS
  - Pharmatelligence
    
    SOW_BPN14770_FXS Publications_10.2023
    
    SoW_CPRD Data Arrangement (Andrew Cooper)
    
    SOW_Rizmoic_Abstracts and Posters_03.2024
    
    SoW_Rizmoic_Consequence publications_03.2023
    
    SoW_Rizmoic_CPRD analysis for methadone therapy_01.2023
    
    SoW_Rizmoic_Epi and baseline CPRD Project_01.2023
    
    SoW_Rizmoic_Methadone publications_03.2023
    
    SoW_Rizmoic_Post operative OIC publications_03.2023
    
    SoW_Rizmoic_Post-operative constipation study_12.2022
    
    SOW_Zatolmilast_FXS Clinical Trials Analysis_01.2024
    
    SOW_Zatolmilast_FXS European Burden of Illness Study_01.2024
  - PHE
  - Putnam
  - RCSI
  - Remap Consulting GmbH
    
    SOW_Fectroja_Net price and access potential in Australia_03.2024
    
    SOW_Olorofim_Access pathways and price potential in 21 markets_07.2023
    
    SOW_Olorofim_Access Pathways Assessment - additional scope_11.2023
    
    SOW_S-309309_Obesity HTA landscape_03.2024
    
    SOW_S-606001_Pompe disease registry opportunities_08.2024
  - RJW&partners Limited
    
    SOW_oral combination of ceftibuten_Payer landscape and analogue analysis_07.2024
  - RTI Health Solutions
    
    SOW_Zatolmilast_Feasibility Assessment for Registry in EU
  - S-005151 Study
  - SAABOA
    
    SOW_BPN14770_EU Care Pathway_06.2023
    
    SoW_BPN14770_Fragile X Market access support Part 1_11.2022
    
    SOW_BPN14770_Fragile X Market access support Part 2_12.2022
    
    SOW_BPN14770_US Payer Ad Board_06.2023
    
    SOW_RWE Vision Phase 1 Benchmark_04.2024
    
    SOW_RWE Vision Phase 2 Develop_04.2024
    
    SOW_RWE Vision Phase 3 Implement_04.2024
    
    SOW_Zatolmilast_FXS IEP Phase 1 Benchmark_04.2024
    
    SOW_Zatolmilast_FXS IEP Phase 2 Identify_04.2024
    
    SOW_Zatolmilast_FXS IEP Phase 3 Assess_04.2024
    
    SOW_Zatolmilast_Market Access Payer Narrative_10.2023
  - Safira
  - SAFIRA Clinical Research Ltd
  - Sciterion Limited under Havas So Group Ltd
    
    SoW_Account management and strategy 2023
    
    SoW_Rizmoic_Account management 2022
    
    SoW_Rizmoic_EFIC congress activity 2022
  - Soft/Export Ltd d.b.a. RareDataEU
    
    SOW_Zatolmilast_Soft/Export Ltd d.b.a. RareDataEU_03.2024
  - Syneos Health Consulting
    
    SOW_Ensitrelvir_Access Mapping + 43 Topics_28.07.2023
  - Templates
  - Tolley Health Economics
  - Transperfect Translations Ltd
  - TriNetX LLC
    
    SOW_Cefiderocol_BSI addition in the US label
  - Trinity
  - Twin Helix Pty Ltd (trading as HTAccess Consulting)
  - University of Birmingham
    
    Studentship Agreement_NWheeler Microbiology and Infection 1004065
  - Uptake Strategies Limited
    
    SOW_Shionogi EU Market Access team structure, capabilities, roles, governance processes_03.2024
  - Verasseti
    
    SoW_gHCVa KMNet_RWE Study Managment (Andrew Cooper)
    
    SOW_KMNet Annual Support 05.2024-04.2025
    
    SOW_KMNet Document Co-Authoring Update_07.2024
    
    SOW_KMNet Lauch Tracker_10.2023
    
    SOW_KMNet Launch Tracker Training Session_02.2024
    
    SOW_KMNet_Org. Chart_12.2023
    
    SOW_Launch tracker screen update_05.2024
    
    SOW_Verasseti Ltd_KMNet Document Co-Authoring
  - Vista Health Pte Ltd
    
    SoW_Fragile X Market Landscaping China and Japan Expanded Scope_07.2023
    
    SoW_Fragile X Market Landscaping China and Japan_02.2023
    
    SOW_Zatolmilast_FXS_Market Launch Preparedness_02.2024
    
    Zatolmilast market launch preparedness - expanded scope_06.2024
  - Wickstrom & Langkilde ApS
  - WNS
    
    MSA
    
    SOW_Pricing and reimbursement analysis for Inhaled Tigecycline_07.2024
    
    SOW_S-337395_PRO Strategy for Adult RSV_05.2024
    
    SOW_S-606001_PRO Strategy for Prompe_06.2024
    
    SoW_S-740792 QPEX oral product_SLR for cUTI_08.2024
  - YHEC
    
    SOW_Cefiderocol_CEM - additional scope_06.2024
    
    SOW_Cefiderocol_CEM - additional scope_07.2024
    
    SOW_Cefiderocol_CEM Update Meta-Analysis_09.2023
    
    SOW_Cefiderocol_Model Streamlining_05.2024
- Operational Excellence
  - Benchmarking
  - Compliance
    
    SBV
    
    SI
  - Conferences
  - Countries
  - GMAx KMNet
  - MAx Objectives
    
    GMAx Objectives
    
    EU MAx Objectives
  - MMIT Managed Care Engagement Platform
  - Organization Charts
  - PBO Response
  - Pricing Governance
  - Real World Evidence
    
    WH launch plan
    
    EU Revive
    
    Congresses
    
    EMAS 2015
    
    Abs simposia
    
    EMAS 2017
    
    ICSM 2015
    
    IMS 2016
    
    ISGE 2016
    
    SIGO 2015 (Italian)
    
    SIM 2015 (Italian)
    
    Guidelines
    
    International
    
    Italy
    
    Media
    
    Media Tutorial - June 2015
    
    Press Conference - Italy December 2015
    
    Meetings
    
    Publications
    
    EU differences by Country
    
    EU Revive
    
    EU vs US
    
    Italy
    
    Spain
    
    United Kingdom
    
    EVES Study
    
    Congresses
    
    IMS 2016
    
    ISGE 2018
    
    NAMS 2018
    
    World Congress on Human Reproduction 2015
    
    Guidelines
    
    International
    
    Italy
    
    SHARE
    
    White Paper
    
    RWE Newsletter
    
    SOP
    
    Studies
  - SEU Newsletters
  - Shionogi
  - Templates
  - TPP
  - Value Drivers
    
    Oncology
  - Ways of Working
My Workspace
- My Folders
  - James Folder for Testing
    
    Arena_dev
    
    access_10_engine
    
    App_Code
    
    App_Data
    
    App_Themes
    
    AstellasPricing
    
    images
    
    styles
    
    Finisterre
    
    images
    
    styles
    
    GSKBlue
    
    images
    
    styles
    
    Hanover
    
    Verasseti
    
    images
    
    styles
    
    ViiVApprovals
    
    htc
    
    images
    
    styles
    
    aspnet_client
    
    system_web
    
    2_0_50727
    
    4_0_30319
    
    Bin
    
    chart_js
    
    docs
    
    samples
    
    site
    
    assets
    
    css
    
    datatables
    
    current_system
    
    dataload
    
    dbbackup
    
    dbscripts
    
    dataload
    
    Articles
  - New Folder

Complete

File successfully added

Country	Reference Type
Croatia
FYR Macedonia
Greece
Italy
Serbia